Thailand
Thailand

Time filter

Source Type

Browse 187 tables and figures, 11 company profiles spread across 114 pages at http://www.reportsnreports.com/reports/804430-global-mandelic-acid-market-research-report-2017.html . Market Segment by Regions, this report splits Global into several key Region, with production, consumption, revenue, market share and growth rate of Mandelic Acid in these regions, from 2012 to 2022 (forecast), like North America, China, Europe, Japan, India, Southeast Asia split by product type, with production, revenue, price, market share and growth rate of each type Split by application, this report focuses on consumption, market share and growth rate of Mandelic Acid in each application. This report studies Mandelic Acid in global market, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering Keyuan Biopharm, Runder Pharmda, Zhongke Hua Ang, Hanhong, Xinhetai Science & Technology, Smart Chemicals, BIOTEC, Chunwangda, TNJ, FUXING and R.L.CHEMICAL. Order a copy at http://www.reportsnreports.com/purchase.aspx?name=804430 . The United States Mandelic Acid Industry, 2012-2022 Market Research Report'' is a professional and in-depth study on the current state of the United States Mandelic Acid industry with a focus on the United States market. The report provides key statistics on the market status of the Mandelic Acid manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company. Through the statistical analysis, the report depicts the United States total market of Mandelic Acid industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2017-2022 market development trends of Mandelic Acid industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Mandelic Acid Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2012-2022 United States Mandelic Acid industry covering all important parameters. The Global and Chinese Mandelic acid Industry 2017 Market Research Report is a professional and in-depth study on the current state of the Mandelic acid industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Mandelic acid market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development status. Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin. This report studies Load Mandelic Acid in Europe market, focuses on price, sales, revenue of each type in Europe. This report also focuses on the sales (consumption), production, import and export of Load Mandelic Acid in global market, forecast to 2022, from 2017. Firstly, this report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers. Second on basis of segments by manufacturers, this report focuses on the sales, price of each type, average price of Load Mandelic Acid, revenue and market share, for key manufacturers. The Load Mandelic Acid industry development trends and marketing channels are also analyzed and the feasibility of new investment projects are assessed and overall research conclusions offered. With the tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers. Connect With Us On:


Browse 187 tables and figures, 11 company profiles spread across 114 pages at http://www.reportsnreports.com/reports/804430-global-mandelic-acid-market-research-report-2017.html . Market Segment by Regions, this report splits Global into several key Region, with production, consumption, revenue, market share and growth rate of Mandelic Acid in these regions, from 2012 to 2022 (forecast), like North America, China, Europe, Japan, India, Southeast Asia split by product type, with production, revenue, price, market share and growth rate of each type Split by application, this report focuses on consumption, market share and growth rate of Mandelic Acid in each application. This report studies Mandelic Acid in global market, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering Keyuan Biopharm, Runder Pharmda, Zhongke Hua Ang, Hanhong, Xinhetai Science & Technology, Smart Chemicals, BIOTEC, Chunwangda, TNJ, FUXING and R.L.CHEMICAL. Order a copy at http://www.reportsnreports.com/purchase.aspx?name=804430 . The United States Mandelic Acid Industry, 2012-2022 Market Research Report'' is a professional and in-depth study on the current state of the United States Mandelic Acid industry with a focus on the United States market. The report provides key statistics on the market status of the Mandelic Acid manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company. Through the statistical analysis, the report depicts the United States total market of Mandelic Acid industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2017-2022 market development trends of Mandelic Acid industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Mandelic Acid Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2012-2022 United States Mandelic Acid industry covering all important parameters. The Global and Chinese Mandelic acid Industry 2017 Market Research Report is a professional and in-depth study on the current state of the Mandelic acid industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Mandelic acid market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development status. Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin. This report studies Load Mandelic Acid in Europe market, focuses on price, sales, revenue of each type in Europe. This report also focuses on the sales (consumption), production, import and export of Load Mandelic Acid in global market, forecast to 2022, from 2017. Firstly, this report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers. Second on basis of segments by manufacturers, this report focuses on the sales, price of each type, average price of Load Mandelic Acid, revenue and market share, for key manufacturers. The Load Mandelic Acid industry development trends and marketing channels are also analyzed and the feasibility of new investment projects are assessed and overall research conclusions offered. With the tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers. Connect With Us On:


News Article | May 23, 2017
Site: www.prweb.com

Pluripotent stem cells (PSCs) offer an unlimited source of human cardiovascular cells for research and the development of cardiac regeneration therapies. The development of highly efficient cardiac-directed differentiation methods makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation efficiencies, further enrichment of CM populations for downstream applications is essential. Recently, a CM-specific cell surface marker called SIRPa (signal-regulatory protein alpha, also termed CD172a) was reported to be a useful tool for flow sorting of human stem cell–derived CMs. However, our expression analysis revealed that SIRPa only labels a subpopulation of CMs indicated by cardiac Troponin T (cTnT) expression. Moreover, SIRPa is also expressed on a sub population of non-CMs, hence making SIRa an inadequate marker to enrich PSC-derived CMs. In this webinar, sponsored by the team at Miltenyi Biotec, participants will have a chance to review human induced pluripotent stem cell derivation, cardiac directed differentiation to human pluripotent stem cell cardiomyocytes (hPSC-CMs), enrichment of hPSC-CMs and subsequent formation of 2D monolayers of electrically connected cells. They will also learn of the generation of purified human induced pluripotent stem cell derived cardiomyocyte. The speaker for this event will be Dr. Todd J. Herron, director of the Frankel Cardiovascular Center's Cardiovascular Regeneration Core Laboratory and Assistant Research Professor at the University of Michigan Center for Arrhythmia Research. Herron currently serves as the director of the Frankel Cardiovascular Center's Cardiovascular Regeneration Core Laboratory, as well as holding a position on the faculty in the University of Michigan Medical School and has appointments in the Department of Internal Medicine and Molecular & Integrative Physiology as Associate Research Scientist. His research is focused on the complex interplay between cardiac electrical excitation and contractile force generation-a process known classically as excitation-contraction coupling. LabRoots will host the event June 7, 2017, beginning at 9 a.m. PDT, 12 p.m. EDT. To read more about this event, learn about the continuing education credits offered, or to register for free, click here. ABOUT MILTENYI BIOTEC Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company’s innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Miltenyi Biotec’s technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Their more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In their commitment to the scientific community, Miltenyi Biotec also offers comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 1,500 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health. ABOUT LABROOTS LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.


News Article | June 13, 2017
Site: www.sciencedaily.com

The human gene MLL is named for the mixed lineage leukemia it creates. Specifically, the gene may break apart and fuse with parts from one of a number of other genes on other chromosomes to create cancer-causing translocations. These translocations make new proteins that have never been seen by the cell and can cause cancerous growth. In addition to mixed lineage leukemia which occurs in children, MLL translocations cause about 15 percent of adult acute myeloid leukemia (AML). Thus MLL has been a major focus of drug development aimed at stopping the cancers caused by these translocations. However, despite their promise, these drugs have struggled to show clinical benefit. A University of Colorado Cancer Center paper published today in the journal Cancer Cell challenges existing understanding of potential therapeutic targets in MLL-translocation leukemia. Specifically, the study shows that within the family of MLL-related proteins, MLL2 and not MLL is the most appropriate target for drugs challenging the disease. In other words, drug developers aiming at MLL may have been missing slightly to one side of the real target. The finding stems from the fact that in these cases of leukemia associated with MLL, only one of the two copies of the gene is altered, meaning that MLL translocations exist alongside the unaffected copy. Previous work had shown that these unaffected copies of MLL -- what researchers call the wildtype form of the gene -- were working with MLL translocations to cause cancer. This finding formed the basis for drug development directed at wildtype MLL. First author of the current paper, Yufei Chen, PhD, describes her early work in this landscape: "When I started my work, there were already a number of studies showing that MLL is very important to maintain this type of leukemia. I wanted to see if I could repeat these findings in a knockout mouse by deleting MLL. But I couldn't see any difference between the control and the knockout." Basically, the existence of wildtype MLL seemed to make no difference to the development of leukemia in these mice. Medicinal chemists had been trying to silence this remaining unaltered and supposedly dangerous MLL, but why would it be worth developing a drug against a target whose removal has no effect on the disease? Of course, Chen was initially skeptical of her results. Surely artifacts of her execution (aka "mistakes") explained her inability to replicate the results of these widely-respected previous studies. Working in the lab of Patricia Ernst, PhD, CU Cancer Center investigator and Professor of Pediatrics and Pharmacology at the CU School of Medicine, Chen, "repeated the experiment, like, a million times," she says. Every time, she got negative results: The silencing of wildtype MLL had no effect on the development of leukemia. Also collaborating on the project was lab assistant Jasmine Lee, undergraduate at UC Denver. If it wasn't experimental procedure, perhaps it was the specific mouse model? To rule out this possibility, Chen got another MLL knockout model from German collaborator A. Francis Stewart, PhD, professor of Genomics and director of the Biotechnology Center (BIOTEC) at Technische Universitat Dresden. "International collaboration made this work possible," Ernst says. "Nobody really goes through the trouble of confirming their results in a second mouse model, but Yufei did it just to be 110 percent sure." Gene knockout in this German model meant the total loss of MLL protein. And yet Chen got the same result: There was no difference in the development of leukemia between mice retaining MLL and the new model that lacked it. "We started with something that was considered established fact, namely that wildtype MLL contributed to MLL translocation leukemia. Then we overturned it," Ernst says. "Still, all this negative data was difficult to explain and we wondered if there was more to the story." To Chen and Ernst, there was something going on in this mix of MLL translocations with MLL wildtype genes. Maybe there was another partner involved? "MLL2 is the most closely related protein to MLL. Some studies suggest that most of the time, MLL and MLL2 have distinct functions. But we wondered if these related genes might be somehow covering for each other," Ernst says. The group was going to need more mouse models. In addition to their MLL knockout, "We got MLL2 knockout and double knockouts," Chen says. At the Functional Genomics Shared Resource at the CU Cancer Center, Chen worked with manager Molisheree Joshi, PhD to recreate these knockouts in human cells as well. Again, when they knocked out MLL, there was no change in the course of leukemia. But when they knocked out MLL2, it resulted in about 40 percent less leukemia. And when they knocked out both MLL and MLL2, they saw about 90 percent reduction in leukemia. Finding that MLL2 may be a target in MLL-translocation leukemia was an important result. But the question of MLL involvement that the group thought it had put to rest (namely the finding that there was no involvement) had now acquired an important nuance: "How can a thing that does nothing on its own -- namely MLL knockout -- have such a dramatic effect when combined with this other thing, namely MLL2 knockout?" Chen asks. "It's a classic synergism," Ernst says. "Like in a car: if you mess with the brakes a little, maybe nothing happens. But if you mess with the brakes a little and also mess with the accelerator so that it sticks, now you've got a problem." Chen took MLL2 knockout leukemia cells to the CU Cancer Center Genomics and Microarray Core Facility to see if she could figure out why the gene collaborated with MLL translocations (and with wildtype MLL) to cause leukemia. Basically, RNA sequencing could tell her how MLL2 was connected to other genes -- what did it turn up or down, and what general pathways did MLL2 influence? It turned out that 177 genes were deregulated by MLL2 alone and that 444 genes were deregulated when both MLL and MLL2 were removed. When viewed together, it turned out that groups of these genes had very significant meaning in the context of leukemia, including members of three leukemia pathways that are already considered significant drug targets in AML. "These are all very important leukemia pathways," Ernst says. "If you had a drug for MLL2, you could hit these really big targets." Additionally, while MLL is essential to the function of healthy bone marrow stem cells, MLL2 seems to have little function in the adult body. This means that targeting MLL2 may come with fewer side effects. Of course, the group's continuing work is making the case for the development of exactly this kind of drug. Chen is working with cells from human cancer patient samples provided by CU Cancer Center investigator Daniel Pollyea, MD and Children's Colorado investigator Kelly Maloney, MD, to show that the effect of MLL2 inhibition is not specific to mouse biology. And Ernst is working to show how broadly relevant MLL2 as a drug target may be in other blood cancers. According to Ernst, this study exemplifies the results that can come from utilizing the full technological resources of a major academic and medical campus, paired with collaboration between investigators across the spectrum of basic to clinical research. "This is a great example of researchers working together," Ernst says. "This basic science has the real potential to affect the development of future drugs that could improve the lives of patients with these conditions."


News Article | June 13, 2017
Site: www.eurekalert.org

The human gene MLL is named for the mixed lineage leukemia it creates. Specifically, the gene may break apart and fuse with parts from one of a number of other genes on other chromosomes to create cancer-causing translocations. These translocations make new proteins that have never been seen by the cell and can cause cancerous growth. In addition to mixed lineage leukemia which occurs in children, MLL translocations cause about 15 percent of adult acute myeloid leukemia (AML). Thus MLL has been a major focus of drug development aimed at stopping the cancers caused by these translocations. However, despite their promise, these drugs have struggled to show clinical benefit. A University of Colorado Cancer Center paper published today in the journal Cancer Cell challenges existing understanding of potential therapeutic targets in MLL-translocation leukemia. Specifically, the study shows that within the family of MLL-related proteins, MLL2 and not MLL is the most appropriate target for drugs challenging the disease. In other words, drug developers aiming at MLL may have been missing slightly to one side of the real target. The finding stems from the fact that in these cases of leukemia associated with MLL, only one of the two copies of the gene is altered, meaning that MLL translocations exist alongside the unaffected copy. Previous work had shown that these unaffected copies of MLL - what researchers call the wildtype form of the gene - were working with MLL translocations to cause cancer. This finding formed the basis for drug development directed at wildtype MLL. First author of the current paper, Yufei Chen, PhD, describes her early work in this landscape: "When I started my work, there were already a number of studies showing that MLL is very important to maintain this type of leukemia. I wanted to see if I could repeat these findings in a knockout mouse by deleting MLL. But I couldn't see any difference between the control and the knockout." Basically, the existence of wildtype MLL seemed to make no difference to the development of leukemia in these mice. Medicinal chemists had been trying to silence this remaining unaltered and supposedly dangerous MLL, but why would it be worth developing a drug against a target whose removal has no effect on the disease? Of course, Chen was initially skeptical of her results. Surely artifacts of her execution (aka "mistakes") explained her inability to replicate the results of these widely-respected previous studies. Working in the lab of Patricia Ernst, PhD, CU Cancer Center investigator and Professor of Pediatrics and Pharmacology at the CU School of Medicine, Chen, "repeated the experiment, like, a million times," she says. Every time, she got negative results: The silencing of wildtype MLL had no effect on the development of leukemia. Also collaborating on the project was lab assistant Jasmine Lee, undergraduate at UC Denver. If it wasn't experimental procedure, perhaps it was the specific mouse model? To rule out this possibility, Chen got another MLL knockout model from German collaborator A. Francis Stewart, PhD, professor of Genomics and director of the Biotechnology Center (BIOTEC) at Technische Universitat Dresden. "International collaboration made this work possible," Ernst says. "Nobody really goes through the trouble of confirming their results in a second mouse model, but Yufei did it just to be 110 percent sure." Gene knockout in this German model meant the total loss of MLL protein. And yet Chen got the same result: There was no difference in the development of leukemia between mice retaining MLL and the new model that lacked it. "We started with something that was considered established fact, namely that wildtype MLL contributed to MLL translocation leukemia. Then we overturned it," Ernst says. "Still, all this negative data was difficult to explain and we wondered if there was more to the story." To Chen and Ernst, there was something going on in this mix of MLL translocations with MLL wildtype genes. Maybe there was another partner involved? "MLL2 is the most closely related protein to MLL. Some studies suggest that most of the time, MLL and MLL2 have distinct functions. But we wondered if these related genes might be somehow covering for each other," Ernst says. The group was going to need more mouse models. In addition to their MLL knockout, "We got MLL2 knockout and double knockouts," Chen says. At the Functional Genomics Shared Resource at the CU Cancer Center, Chen worked with manager Molisheree Joshi, PhD to recreate these knockouts in human cells as well. Again, when they knocked out MLL, there was no change in the course of leukemia. But when they knocked out MLL2, it resulted in about 40 percent less leukemia. And when they knocked out both MLL and MLL2, they saw about 90 percent reduction in leukemia. Finding that MLL2 may be a target in MLL-translocation leukemia was an important result. But the question of MLL involvement that the group thought it had put to rest (namely the finding that there was no involvement) had now acquired an important nuance: "How can a thing that does nothing on its own - namely MLL knockout - have such a dramatic effect when combined with this other thing, namely MLL2 knockout?" Chen asks. "It's a classic synergism," Ernst says. "Like in a car: if you mess with the brakes a little, maybe nothing happens. But if you mess with the brakes a little and also mess with the accelerator so that it sticks, now you've got a problem." Chen took MLL2 knockout leukemia cells to the CU Cancer Center Genomics and Microarray Core Facility to see if she could figure out why the gene collaborated with MLL translocations (and with wildtype MLL) to cause leukemia. Basically, RNA sequencing could tell her how MLL2 was connected to other genes - what did it turn up or down, and what general pathways did MLL2 influence? It turned out that 177 genes were deregulated by MLL2 alone and that 444 genes were deregulated when both MLL and MLL2 were removed. When viewed together, it turned out that groups of these genes had very significant meaning in the context of leukemia, including members of three leukemia pathways that are already considered significant drug targets in AML. "These are all very important leukemia pathways," Ernst says. "If you had a drug for MLL2, you could hit these really big targets." Additionally, while MLL is essential to the function of healthy bone marrow stem cells, MLL2 seems to have little function in the adult body. This means that targeting MLL2 may come with fewer side effects. Of course, the group's continuing work is making the case for the development of exactly this kind of drug. Chen is working with cells from human cancer patient samples provided by CU Cancer Center investigator Daniel Pollyea, MD and Children's Colorado investigator Kelly Maloney, MD, to show that the effect of MLL2 inhibition is not specific to mouse biology. And Ernst is working to show how broadly relevant MLL2 as a drug target may be in other blood cancers. According to Ernst, this study exemplifies the results that can come from utilizing the full technological resources of a major academic and medical campus, paired with collaboration between investigators across the spectrum of basic to clinical research. "This is a great example of researchers working together," Ernst says. "This basic science has the real potential to affect the development of future drugs that could improve the lives of patients with these conditions."


HO CHI MINH CITY, Vietnam, Nov. 8, 2016 /PRNewswire/ -- Vietnam's Leading Renewable Energy and Energy Efficiency Exhibition -- RE & EE Vietnam 2016 will open it's premier business platform at Saigon Exhibition and Convention Center (SECC), 799 Nguyen Van Linh, District 7, Ho Chi Minh City, Vietnam from 9 to 11 November 2016. It is organised by UBM Asia and supported by the Vietnam Energy Conservation and Energy Efficiency Association (VECEA), Vietnam Automation (VAA), Energy Conservation Center HCM (ECC - HCM), EU-Vietnam Business Network (EVBN) and Ho Chi Minh Power Corporation (EVN-HCM). This is a unit trade exhibition in Vietnam's power, renewable energy and energy efficiency industry. It will feature different ranges of products, technologies, equipment, and solutions showcased at private booths or international pavilions of local and international enterprises such as CJR Renewables, Conergy Asia, DNV GL Energy, Donasonic, Ecosphere Renewables, EVBN, Green Power Monitor, Ingeteam, Mitsubishi and many others. Come and explore your solutions at RE & EE Vietnam 2016. During the exhibition, a series of insightful activities will provide full information on Vietnam's energy market, it's trends and development as well as introduce new technologies in this industry. Participants can learn from the Ministry of Industry & Trade, ECC- HCM, BIOTEC, King Mongkut's University of Technology Thonburi, and C.F.Nielsen, amongst others at RE & EE Vietnam's Technical Seminars, Workshops and Conference with the theme "Vietnam Energy Forum: Toward Sustainable Energy Development in Vietnam." Find out the full agenda and book your seat at RE & EE Vietnam's website: http://www.renergyvietnam.com/en-us/highlights/conference. Owned by UBM plc listed on the London Stock Exchange, UBM Asia is the largest trade show organiser in Asia and the largest commercial organiser in China, India and Malaysia. Established with its headquarters in Hong Kong and subsidiary companies across Asia and in the US, UBM Asia has strong global network of 30 offices and 1,400 staff in 25 major cities. We operate in 21 market sectors with 235 exhibitions and conferences, 28 targeted trade publications, 18 vertical portals for over 1,000,000 quality exhibitors, visitors, conference delegates, advertisers and subscribers from all over the world.


HO CHI MINH CITY, Vietnam, Nov. 8, 2016 /PRNewswire/ -- Vietnam's Leading Renewable Energy and Energy Efficiency Exhibition -- RE & EE Vietnam 2016 will open it's premier business platform at Saigon Exhibition and Convention Center (SECC), 799 Nguyen Van Linh, District 7, Ho Chi Minh City, Vietnam from 9 to 11 November 2016. It is organised by UBM Asia and supported by the Vietnam Energy Conservation and Energy Efficiency Association (VECEA), Vietnam Automation (VAA), Energy Conservation Center HCM (ECC - HCM), EU-Vietnam Business Network (EVBN) and Ho Chi Minh Power Corporation (EVN-HCM). This is a unit trade exhibition in Vietnam's power, renewable energy and energy efficiency industry. It will feature different ranges of products, technologies, equipment, and solutions showcased at private booths or international pavilions of local and international enterprises such as CJR Renewables, Conergy Asia, DNV GL Energy, Donasonic, Ecosphere Renewables, EVBN, Green Power Monitor, Ingeteam, Mitsubishi and many others. Come and explore your solutions at RE & EE Vietnam 2016. During the exhibition, a series of insightful activities will provide full information on Vietnam's energy market, it's trends and development as well as introduce new technologies in this industry. Participants can learn from the Ministry of Industry & Trade, ECC- HCM, BIOTEC, King Mongkut's University of Technology Thonburi, and C.F.Nielsen, amongst others at RE & EE Vietnam's Technical Seminars, Workshops and Conference with the theme "Vietnam Energy Forum: Toward Sustainable Energy Development in Vietnam." Find out the full agenda and book your seat at RE & EE Vietnam's website: http://www.renergyvietnam.com/en-us/highlights/conference. Owned by UBM plc listed on the London Stock Exchange, UBM Asia is the largest trade show organiser in Asia and the largest commercial organiser in China, India and Malaysia. Established with its headquarters in Hong Kong and subsidiary companies across Asia and in the US, UBM Asia has strong global network of 30 offices and 1,400 staff in 25 major cities. We operate in 21 market sectors with 235 exhibitions and conferences, 28 targeted trade publications, 18 vertical portals for over 1,000,000 quality exhibitors, visitors, conference delegates, advertisers and subscribers from all over the world.


Global Electrophoresis Systems Market Outlook 2016-2021 has been prepared based on the synthesis, analysis, and interpretation of information about the global Electrophoresis Systems market collected from specialized sources. Albany, NY, November 25, 2016 --( Request For Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=808315 Initially, the report segments the market on the basis of types, applications and geographically segmented by above regions along with the production, consumption and import/export. Further, every segment is classified and analyzed on the basis of product types, application and the end-use industries of the global market. There are several methodical tools which are used in the research such as investment returns, feasibility and market effect factor analysis to present a comprehensive study of the market for electrophoresis system across the world. The report describes the electrophoresis system process in order to understand the whole concept. Electrophoresis systems are devices that are used to separate molecules based on their charge and size as they move through a solution under the influence of an electric field. There are several uses of an electrophoresis system such as: • It is used for both DNA and RNA analysis. • This is the most suitable technique used in laboratories in order to separate macromolecules. • It can be also used for qualitative or quantitative analysis of different materials, or material component analysis as well as single component extraction and preparation. Electrophoresis systems are purely based on the principle of design and manufacture. The report offers major statistics on the state of the industry which acts as a valuable source of guidance for readers and direction for companies who are interested in this market. The key leaders of the Electrophoresis system in the global market are mentioned below: • Analytik Jena • Cleaver Scientific • GE Healthcare Life Sciences • Agilent Technologies • Syngene • Labnet International • SCILOGEX • BIOTEC-FISCHER • CELL - Start Project • Auxilab S.L • BPC BioSed • Sage Science • Helena Biosciences • Bio-Rad • Sebia • SCIEX • UVP • VWR • Texas BioGene Read Full Report with TOC: http://www.marketresearchhub.com/report/global-electrophoresis-systems-market-research-report-2016-report.html The study also covers key technological developments in the coming years. Leading players mentioned along with their key strategies, manufacturing base and competitors list. Moreover, the competitive landscape section of the report provides a clear insight into the market share analysis of industry players. At the end, upstream raw materials, equipment’s and downstream demand analysis is also presented out in the report. About Market Research Hub: Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps. MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Contact Details: 90 State Street, Albany, NY 12207, United States Toll Free: 866-997-4948 (US-Canada) Tel: +1-518-621-2074 Email: press@marketresearchhub.com Website: http://www.marketresearchhub.com Albany, NY, November 25, 2016 --( PR.com )-- Market Research Hub has recently added a new report titled “Global Electrophoresis Systems Market Research Report 2016,” to its offerings. This research report is a professional and in-depth study on the current state of the electrophoresis system industry from 2011-2016. Additionally, it also provides extensive market forecasts from 2011 to 2021 by different regions. Key regions highlighted in the report are North America, Europe, China, Japan, Korea and Taiwan.Request For Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=808315Initially, the report segments the market on the basis of types, applications and geographically segmented by above regions along with the production, consumption and import/export. Further, every segment is classified and analyzed on the basis of product types, application and the end-use industries of the global market. There are several methodical tools which are used in the research such as investment returns, feasibility and market effect factor analysis to present a comprehensive study of the market for electrophoresis system across the world.The report describes the electrophoresis system process in order to understand the whole concept. Electrophoresis systems are devices that are used to separate molecules based on their charge and size as they move through a solution under the influence of an electric field. There are several uses of an electrophoresis system such as:• It is used for both DNA and RNA analysis.• This is the most suitable technique used in laboratories in order to separate macromolecules.• It can be also used for qualitative or quantitative analysis of different materials, or material component analysis as well as single component extraction and preparation.Electrophoresis systems are purely based on the principle of design and manufacture. The report offers major statistics on the state of the industry which acts as a valuable source of guidance for readers and direction for companies who are interested in this market.The key leaders of the Electrophoresis system in the global market are mentioned below:• Analytik Jena• Cleaver Scientific• GE Healthcare Life Sciences• Agilent Technologies• Syngene• Labnet International• SCILOGEX• BIOTEC-FISCHER• CELL - Start Project• Auxilab S.L• BPC BioSed• Sage Science• Helena Biosciences• Bio-Rad• Sebia• SCIEX• UVP• VWR• Texas BioGeneRead Full Report with TOC: http://www.marketresearchhub.com/report/global-electrophoresis-systems-market-research-report-2016-report.htmlThe study also covers key technological developments in the coming years. Leading players mentioned along with their key strategies, manufacturing base and competitors list. Moreover, the competitive landscape section of the report provides a clear insight into the market share analysis of industry players. At the end, upstream raw materials, equipment’s and downstream demand analysis is also presented out in the report.About Market Research Hub:Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.Contact Details:90 State Street,Albany, NY 12207,United StatesToll Free: 866-997-4948 (US-Canada)Tel: +1-518-621-2074Email: press@marketresearchhub.comWebsite: http://www.marketresearchhub.com Click here to view the list of recent Press Releases from Market Research Hub


News Article | November 21, 2016
Site: www.newsmaker.com.au

This report studies Antibodies in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering  ABCAM  ABNOVA  ABD SEROTEC (BIO-RAD)  ACTIVE MOTIF  BD BIOSCIENCES  BECKMAN COULTER  BETHYL LABORATORIES  BIOLEGEND  BIO-TECHNE  CELL SIGNALING TECHNOLOGY  DAKO  EBIOSCIENCE  EMD MILLIPORE  EVEREST BIOTECH  JACKSON IMMUNORESEARCH LABORATORIES  LIFESPAN BIOSCIENCES  MILTENYI BIOTEC GMBH  MILTENYI BIOTEC  MORPHOSYS AG  ORIGENE TECHNOLOGIES Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Antibodies in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  Type I  Type II  Type III Split by application, this report focuses on consumption, market share and growth rate of Antibodies in each application, can be divided into  Application 1  Application 2  Application 3 Global Antibodies Market Research Report 2016  1 Antibodies Market Overview  1.1 Product Overview and Scope of Antibodies  1.2 Antibodies Segment by Type  1.2.1 Global Production Market Share of Antibodies by Type in 2015  1.2.2 Type I  1.2.3 Type II  1.2.4 Type III  1.3 Antibodies Segment by Application  1.3.1 Antibodies Consumption Market Share by Application in 2015  1.3.2 Application 1  1.3.3 Application 2  1.3.4 Application 3  1.4 Antibodies Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of Antibodies (2011-2021) 7 Global Antibodies Manufacturers Profiles/Analysis  7.1 ABCAM  7.1.1 Company Basic Information, Manufacturing Base and Its Competitors  7.1.2 Antibodies Product Type, Application and Specification  7.1.2.1 Type I  7.1.2.2 Type II  7.1.3 ABCAM Antibodies Production, Revenue, Price and Gross Margin (2015 and 2016)  7.1.4 Main Business/Business Overview  7.2 ABNOVA  7.2.1 Company Basic Information, Manufacturing Base and Its Competitors  7.2.2 Antibodies Product Type, Application and Specification  7.2.2.1 Type I  7.2.2.2 Type II  7.2.3 ABNOVA Antibodies Production, Revenue, Price and Gross Margin (2015 and 2016)  7.2.4 Main Business/Business Overview  7.3 ABD SEROTEC (BIO-RAD)  7.3.1 Company Basic Information, Manufacturing Base and Its Competitors  7.3.2 Antibodies Product Type, Application and Specification  7.3.2.1 Type I  7.3.2.2 Type II  7.3.3 ABD SEROTEC (BIO-RAD) Antibodies Production, Revenue, Price and Gross Margin (2015 and 2016)  7.3.4 Main Business/Business Overview  7.4 ACTIVE MOTIF  7.4.1 Company Basic Information, Manufacturing Base and Its Competitors  7.4.2 Antibodies Product Type, Application and Specification  7.4.2.1 Type I  7.4.2.2 Type II  7.4.3 ACTIVE MOTIF Antibodies Production, Revenue, Price and Gross Margin (2015 and 2016)  7.4.4 Main Business/Business Overview  7.5 BD BIOSCIENCES  7.5.1 Company Basic Information, Manufacturing Base and Its Competitors  7.5.2 Antibodies Product Type, Application and Specification  7.5.2.1 Type I  7.5.2.2 Type II  7.5.3 BD BIOSCIENCES Antibodies Production, Revenue, Price and Gross Margin (2015 and 2016)  7.5.4 Main Business/Business Overview  7.6 BECKMAN COULTER  7.6.1 Company Basic Information, Manufacturing Base and Its Competitors  7.6.2 Antibodies Product Type, Application and Specification  7.6.2.1 Type I  7.6.2.2 Type II  7.6.3 BECKMAN COULTER Antibodies Production, Revenue, Price and Gross Margin (2015 and 2016)  7.6.4 Main Business/Business Overview  7.7 BETHYL LABORATORIES  7.7.1 Company Basic Information, Manufacturing Base and Its Competitors  7.7.2 Antibodies Product Type, Application and Specification  7.7.2.1 Type I  7.7.2.2 Type II  7.7.3 BETHYL LABORATORIES Antibodies Production, Revenue, Price and Gross Margin (2015 and 2016)  7.7.4 Main Business/Business Overview  7.8 BIOLEGEND  7.8.1 Company Basic Information, Manufacturing Base and Its Competitors  7.8.2 Antibodies Product Type, Application and Specification  7.8.2.1 Type I  7.8.2.2 Type II  7.8.3 BIOLEGEND Antibodies Production, Revenue, Price and Gross Margin (2015 and 2016)  7.8.4 Main Business/Business Overview  7.9 BIO-TECHNE  7.9.1 Company Basic Information, Manufacturing Base and Its Competitors  7.9.2 Antibodies Product Type, Application and Specification  7.9.2.1 Type I  7.9.2.2 Type II  7.9.3 BIO-TECHNE Antibodies Production, Revenue, Price and Gross Margin (2015 and 2016)  7.9.4 Main Business/Business Overview  7.10 CELL SIGNALING TECHNOLOGY  7.10.1 Company Basic Information, Manufacturing Base and Its Competitors  7.10.2 Antibodies Product Type, Application and Specification  7.10.2.1 Type I  7.10.2.2 Type II  7.10.3 CELL SIGNALING TECHNOLOGY Antibodies Production, Revenue, Price and Gross Margin (2015 and 2016)  7.10.4 Main Business/Business Overview  7.11 DAKO  7.12 EBIOSCIENCE  7.13 EMD MILLIPORE  7.14 EVEREST BIOTECH  7.15 JACKSON IMMUNORESEARCH LABORATORIES  7.16 LIFESPAN BIOSCIENCES  7.17 MILTENYI BIOTEC GMBH  7.18 MILTENYI BIOTEC  7.19 MORPHOSYS AG  7.20 ORIGENE TECHNOLOGIES


News Article | November 17, 2016
Site: www.newsmaker.com.au

report focuses on the major drivers and restraints for the key players. It also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Blotting Systems Market research report is a professional and in-depth study on the current state of the Blotting Systems Industry. In depth analysis of Blotting Systems Market is a crucial thing for various stakeholders like investors, CEOs, traders, suppliers and others. The Blotting Systems Market research report is a resource, which provides technical and financial details of the industry. Browse more detail information about Blotting Systems Market at: To begin with, the report elaborates the Blotting Systems Market overview. Various definitions and classification of the industry, applications of the industry and chain structure are given. Present day status of the Blotting Systems Market in key regions is stated and industry policies and news are analysed. Next part of the Blotting Systems Market Industry analysis report speaks about the manufacturing process. The process is analysed thoroughly with respect three points, viz. raw material and equipment suppliers, various manufacturing associated costs (material cost, labour cost, etc.) and the actual process. Get a PDF Sample of Blotting Systems Market Research Report at: Following are the key players covered in this Blotting Systems Market research report: Applied Biosystems BIOTEC-FISCHER No. of Report Pages: 113 Price of Report (Single User Licence): $ 2900 Purchase the Report Now @ After the basic information, the Blotting Systems Market report sheds light on the production. Production plants, their capacities, global production and revenue are studied. Also, the Blotting Systems Market growth in various regions and R&D status are also covered. Following are Major Table of Content of Blotting Systems Industry: • Blotting Systems Market Competition by Manufacturers • Blotting Systems Production, Revenue (Value) by Region (2011-2021) • Blotting Systems Supply (Production), Consumption, Export, Import by Regions (2011-2021) • Blotting Systems Production, Revenue (Value), Price Trend by Type • Blotting Systems Market Analysis by Application • Blotting Systems Manufacturers Profiles/Analysis • Blotting Systems Manufacturing Cost Analysis • Industrial Chain, Sourcing Strategy and Downstream Buyers • Blotting Systems Market Forecast (2016-2021) Get Discount on Blotting Systems Market Research Report at:   Further in the Blotting Systems Market Industry Analysis report, the Blotting Systems Market is examined for price, cost and gross. These three points are analysed for types, companies and regions. In continuation with this data sale price is for various types, applications and region is also included. The Blotting Systems Market for major regions is given. Additionally, type wise and application wise consumption figures are also given. Scope of the Blotting Systems Industry on the basis of region: • North America • China • Europe • Japan • India • Southeast Asia With the help of supply and consumption data, gap between these two is also explained. Have any query before Buying Report or Need Customized Report? Contact us at @ To provide information on competitive landscape, this report includes detailed profiles of Blotting Systems Market key players. For each player, product details, capacity, price, cost, gross and revenue numbers are given. Their contact information is provided for better understanding. In this Blotting Systems Market report analysis, traders and distributors analysis is given along with contact details. For material and equipment suppliers also, contact details are given. New investment feasibility analysis and Blotting Systems Market Industry growth is included in the report. About Absolute Reports: Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters. Contact– Mr. Ameya Pingaley Absolute Reports +1-408 520 9750 Email –   

Loading BIOTEC collaborators
Loading BIOTEC collaborators